NASDAQ:VPHM - Shire Viropharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week Range$23.13 - $50.01VolumeN/AAverage VolumeN/AMarket Capitalization$3.30 billionP/E RatioN/ADividend YieldN/ABeta2.14 Company ProfileDiscussionChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ViroPharma Incorporated (ViroPharma) is biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich's Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich's Ataxia). On January 23, 2014, Shire Plc completed tender offer for 79.5% of ViroPharma Inc. Receive VPHM News and Ratings via Email Sign-up to receive the latest news and ratings for VPHM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryPharmaceuticals SectorN/A SymbolNASDAQ:VPHM CUSIP92824110 Webwww.viropharma.com Phone+1-610-4587300 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares65,860,000Market Cap$3.30 billion Shire Viropharma (NASDAQ:VPHM) Frequently Asked Questions What is Shire Viropharma's stock symbol? Shire Viropharma trades on the NASDAQ under the ticker symbol "VPHM." How were Shire Viropharma's earnings last quarter? Shire Viropharma Inc (NASDAQ:VPHM) issued its quarterly earnings data on Thursday, October, 24th. The biotechnology company reported $0.20 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.05 by $0.15. The biotechnology company earned $113 million during the quarter, compared to the consensus estimate of $113.35 million. Shire Viropharma's revenue for the quarter was up 24.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.10 earnings per share. View Shire Viropharma's Earnings History. How do I buy shares of Shire Viropharma? Shares of VPHM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How big of a company is Shire Viropharma? Shire Viropharma has a market capitalization of $3.30 billion. What is Shire Viropharma's official website? The official website for Shire Viropharma is http://www.viropharma.com. How can I contact Shire Viropharma? Shire Viropharma's mailing address is 730 Stockton Dr, EXTON, PA 19341-1171, United States. The biotechnology company can be reached via phone at +1-610-4587300. MarketBeat Community Rating for Shire Viropharma (NASDAQ VPHM)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 208 (Vote Outperform)Underperform Votes: 291 (Vote Underperform)Total Votes: 499MarketBeat's community ratings are surveys of what our community members think about Shire Viropharma and other stocks. Vote "Outperform" if you believe VPHM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VPHM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/22/2018 by MarketBeat.com StaffFeatured Article: What is a Fiduciary?